ENXTPA:VETO

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region.


Snowflake Analysis

Flawless balance sheet with moderate growth potential.


Similar Companies

Share Price & News

How has Vetoquinol's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: VETO's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-3.2%

VETO

-0.2%

FR Pharmaceuticals

-24.4%

FR Market


1 Year Return

0.7%

VETO

10.6%

FR Pharmaceuticals

-14.3%

FR Market

Return vs Industry: VETO underperformed the French Pharmaceuticals industry which returned 10.6% over the past year.

Return vs Market: VETO exceeded the French Market which returned -14.3% over the past year.


Shareholder returns

VETOIndustryMarket
7 Day-3.2%-0.2%-24.4%
30 Day-3.9%-3.9%-26.1%
90 Day-20.6%-5.0%-21.6%
1 Year1.7%0.7%14.3%10.6%-12.4%-14.3%
3 Year14.3%11.3%7.3%-4.2%-2.9%-11.1%
5 Year56.9%49.4%18.2%-2.0%12.5%-2.1%

Price Volatility Vs. Market

How volatile is Vetoquinol's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Vetoquinol undervalued compared to its fair value and its price relative to the market?

22.35x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: VETO (€54) is trading above our estimate of fair value (€44.57)

Significantly Below Fair Value: VETO is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: VETO is good value based on its PE Ratio (22.3x) compared to the Pharmaceuticals industry average (22.3x).

PE vs Market: VETO is poor value based on its PE Ratio (22.3x) compared to the French market (14x).


Price to Earnings Growth Ratio

PEG Ratio: VETO is poor value based on its PEG Ratio (1.2x)


Price to Book Ratio

PB vs Industry: VETO is good value based on its PB Ratio (1.7x) compared to the FR Pharmaceuticals industry average (2.4x).


Next Steps

Future Growth

How is Vetoquinol forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

18.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: VETO's forecast earnings growth (18.1% per year) is above the savings rate (0.6%).

Earnings vs Market: VETO's earnings (18.1% per year) are forecast to grow faster than the French market (13.1% per year).

High Growth Earnings: VETO's earnings are forecast to grow, but not significantly.

Revenue vs Market: VETO's revenue (6.8% per year) is forecast to grow faster than the French market (4% per year).

High Growth Revenue: VETO's revenue (6.8% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: VETO's Return on Equity is forecast to be low in 3 years time (9.4%).


Next Steps

Past Performance

How has Vetoquinol performed over the past 5 years?

6.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: VETO has high quality earnings.

Growing Profit Margin: VETO's current net profit margins (7.2%) are lower than last year (9.9%).


Past Earnings Growth Analysis

Earnings Trend: VETO's earnings have grown by 6.7% per year over the past 5 years.

Accelerating Growth: VETO's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: VETO had negative earnings growth (-21.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (7%).


Return on Equity

High ROE: VETO's Return on Equity (7.3%) is considered low.


Next Steps

Financial Health

How is Vetoquinol's financial position?


Financial Position Analysis

Short Term Liabilities: VETO's short term assets (€257.3M) exceed its short term liabilities (€92.7M).

Long Term Liabilities: VETO's short term assets (€257.3M) exceed its long term liabilities (€32.8M).


Debt to Equity History and Analysis

Debt Level: VETO's debt to equity ratio (0.4%) is considered satisfactory.

Reducing Debt: VETO's debt to equity ratio has reduced from 20.8% to 0.4% over the past 5 years.

Debt Coverage: VETO's debt is well covered by operating cash flow (3692.3%).

Interest Coverage: VETO's interest payments on its debt are well covered by EBIT (450.8x coverage).


Balance Sheet


Next Steps

Dividend

What is Vetoquinol's current dividend yield, its reliability and sustainability?

0.70%

Current Dividend Yield


Upcoming Dividend Payment


Dividend Yield vs Market

Notable Dividend: VETO's dividend (0.7%) isn’t notable compared to the bottom 25% of dividend payers in the French market (1.79%).

High Dividend: VETO's dividend (0.7%) is low compared to the top 25% of dividend payers in the French market (5.46%).


Stability and Growth of Payments

Stable Dividend: VETO is not paying a notable dividend for the French market, therefore no need to check if payments are stable.

Growing Dividend: VETO is not paying a notable dividend for the French market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: VETO is not paying a notable dividend for the French market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of VETO's dividend in 3 years as they are not forecast to pay a notable one for the French market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.5yrs

Average management tenure


CEO

Matthieu Frechin (50yo)

10.08yrs

Tenure

€448,815

Compensation

Mr. Matthieu Frechin has been the Chief Executive Officer at Vétoquinol SA since April 01, 2010. Mr. Frechin served as Deputy Chief Executive Officer of Vétoquinol SA from August 21, 2006 and also served a ...


CEO Compensation Analysis

Compensation vs Market: Matthieu's total compensation ($USD488.91K) is below average for companies of similar size in the French market ($USD799.62K).

Compensation vs Earnings: Matthieu's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Matthieu Frechin
CEO & Director10.08yrs€448.82kno data
Jean-Yves Ravinet
Group COO & Deputy GM0.33yr€359.85kno data
Régis du Monteil
Group Director of Finance & Legal9.5yrsno datano data
Dominique Derveaux
Group Chief Operations Officer0.083yrno datano data
Jean Deleforge
Chief Scientific Officer4.5yrsno datano data
Hans Hollegien
Group Director of Marketing & Communicationno datano datano data
Isabelle Proust-Cabrera
Group Director of Human Resourcesno datano datano data

4.5yrs

Average Tenure

54yo

Average Age

Experienced Management: VETO's management team is considered experienced (4.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Matthieu Frechin
CEO & Director10.08yrs€448.82kno data
Étienne Frechin
Chairman of the Board40.33yrs€159.06k4.18% 26.7m
Martine Frechin
Director16yrs€6.00kno data
Jean-Charles Frechin
Director48.42yrs€17.00kno data
Philippe Arnold
Independent Director12.92yrs€17.00kno data
Louis Champel
Independent Director10.75yrs€17.00kno data
Marie-Josèphe Baud
Independent Director7yrs€17.00kno data
Elisabeth Pacaud
Independent Director2yrsno datano data

13.5yrs

Average Tenure

74.5yo

Average Age

Experienced Board: VETO's board of directors are seasoned and experienced ( 13.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Vetoquinol SA's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Vetoquinol SA
  • Ticker: VETO
  • Exchange: ENXTPA
  • Founded: 1933
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €638.918m
  • Shares outstanding: 11.83m
  • Website: https://www.vetoquinol.com

Number of Employees


Location

  • Vetoquinol SA
  • Magny-Vernois
  • 34 rue du ChEne-Sainte-Anne
  • Lure
  • Franche Comté
  • 70204
  • France

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
VETOENXTPA (Euronext Paris)YesOrdinary SharesFREURNov 2006
0O1OLSE (London Stock Exchange)YesOrdinary SharesGBEURNov 2006

Biography

Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of pain management, anti-infective, cardiology-nephrology, care and hygiene, antiparasiticides, behavior, internal medicine, and reproduction for cats, dogs, cattle, and pigs. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/05/25 07:04
End of Day Share Price2020/05/22 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.